Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 229

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Characterisation and manipulation of docetaxel resistant prostate cancer cell lines

Open access
O'Neill, Amanda J, Prencipe, Maria, Dowling, Catherine, Fan, Yue, Mulrane, Laoighse, Gallagher, William M, O'Connor, Darran, O'Connor, Robert, Devery, Aoife, Corcoran, Claire, Rani, Sweta, O'Driscoll, Lorraine, Fitzpatrick, John M, Watson, R William G · 2011 · Molecular Cancer

Abstract

BACKGROUND: There is no effective treatment strategy for advanced castration-resistant prostate cancer. Although Docetaxel (Taxotere®) represents the most active chemotherapeutic agent it only gives a modest survival advantage with most patients eventually progressing because of inherent or acquired drug resistance. The aims of this study were to further investigate the mechanisms of resistance to Docetaxel. Three Docetaxel resistant sub-lines were generated and confirmed to be resistant to the apoptotic and anti-proliferative effects of increasing concentrations of Docetaxel. RESULTS: The resistant DU-145 R and 22RV1 R had expression of P-glycoprotein and its inhibition with Elacridar partially and totally reversed the resistant phenotype in the two cell lines respectively, which was not seen in the PC-3 resistant sublines. Resistance was also not mediated in the PC-3 cells by cellular senescence or autophagy but multiple changes in pro- and anti-apoptotic genes and proteins were demonstrated. Even though there were lower basal levels of NF-κB activity in the PC-3 D12 cells compared to the Parental PC-3, docetaxel induced higher NF-κB activity and IκB phosphorylation at 3 and 6 hours with only minor changes in the DU-145 cells. Inhibition of NF-κB with the BAY 11-7082 inhibitor reversed the resistance to Docetaxel. CONCLUSION: This study confirms that multiple mechanisms contribute to Docetaxel resistance and the central transcription factor NF-κB plays an immensely important role in determining docetaxel-resistance which may represent an appropriate therapeutic target.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/1476-4598-10-126

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Cited by

See all 229

Metadata

Authors
O'Neill, A. J., Prencipe, M., Dowling, C., Fan, Y., Mulrane, L., Gallagher, W. M., O'Connor, D., O'Connor, R., Devery, A., Corcoran, C., Rani, S., O'Driscoll, L., Fitzpatrick, J. M., & Watson, R. W. G.
Venue
Molecular Cancer
Published
2011
Volume
10
Issue
1
Pages
126
ISSN
1476-4598 (ISSN-L)
OpenAlex
W2106572206
Cited by
229
References
7
FWCI
8.17
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Characterisation and manipulation of docetaxel resistant prostate cancer cell lines. https://app.cochat.ai/papers/10.1186/1476-4598-10-126
The paper
O'Neill, A. J., Prencipe, M., Dowling, C., Fan, Y., Mulrane, L., Gallagher, W. M., O'Connor, D., O'Connor, R., Devery, A., Corcoran, C., Rani, S., O'Driscoll, L., Fitzpatrick, J. M., & Watson, R. W. G. (2011). Characterisation and manipulation of docetaxel resistant prostate cancer cell lines. Molecular Cancer. https://doi.org/10.1186/1476-4598-10-126

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.